![Dirk Jan van Ginkel]()
Dirk Jan van Ginkel1, MD; Willem L. Bor1, MD; Christophe L.F. Dubois2, MD, PhD; Hugo M. Aarts3,4, MD; Maxim J.P. Rooijakkers5, MD; Kees H. van Bergeijk6, MD; Liesbeth Rosseel7, MD, PhD; Leo Veenstra8, MD; Ole De Backer9, MD, PhD; Nicolas M. Van Mieghem10, MD, PhD; Frank van der Kley11, MD, PhD; Adriaan Wilgenhof3,12, MD; Remigio Leonora13, MD; Jonathan Halim14, MD; Carl E. Schotborgh15, MD, PhD; Emanuele Barbato16, MD, PhD; Jan A.S. Van Der Heyden17, MD, PhD; Peter Frambach18, MD, PhD; Bert Ferdinande19, MD, PhD; Darren Mylotte20, MD, PhD; Enrico Fabris21, MD, PhD; Benno J.W.M. Rensing1, MD, PhD; Leo Timmers1, MD, PhD; Martin J. Swaans1, MD, PhD; Jorn Brouwer1, MD, PhD; Vincent J. Nijenhuis1, MD, PhD; Joyce Peper1, MSc, PhD; Pieter A. Vriesendorp8, MD, PhD; Bas de Laat22, MSc, PhD; Marisa Ninivaggi22, MSc, PhD; Hendrik Stragier23,24, MD; Michiel Voskuil4, MD, PhD; Alexander J.J. IJsselmuiden14, MD, PhD; Renicus S. Hermanides11, MD, PhD; Pierfrancesco Agostoni11, MD, PhD; Arnoud W.J. van 't Hof8,24, MD, PhD; Joanna J. Wykrzykowska6, MD, PhD; Niels van Royen5, MD, PhD; Ronak Delewi3, MD, PhD; Jurrien M. ten Berg1,24, MD, PhD
1. Department of Cardiology, St. Antonius Hospital, Nieuwegein, the Netherlands; 2. Department of Cardiovascular Medicine, University Hospital Leuven, Leuven, Belgium; 3. Department of Cardiology, Amsterdam UMC, Amsterdam, the Netherlands; 4. Department of Cardiology, University Medical Center Utrecht, Utrecht, the Netherlands; 5. Department of Cardiology, Radboud University Medical Center, Nijmegen, the Netherlands; 6. Department of Cardiology, University Medical Center Groningen, Groningen, the Netherlands; 7. Department of Cardiology, Algemeen Stedelijk Hospital Aalst, Aalst, Belgium; 8. Department of Cardiology, Maastricht University Medical Center, Maastricht, the Netherlands; 9. The Heart Center, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark; 10. Department of Cardiology, Erasmus University Medical Center, Rotterdam, the Netherlands; 11. Department of Cardiology, Leiden University Medical Center, Leiden, the Netherlands; 12. Department of Cardiology, Hospital Network Antwerp (ZNA) Middelheim, Antwerp, Belgium; 13. Department of Cardiology, Isala Hospital, Zwolle, the Netherlands; 14. Department of Cardiology, Amphia Hospital, Breda, the Netherlands; 15. Department of Cardiology, Haga Hospital, The Hague, the Netherlands; 16. Cardiovascular Center Aalst, Onze Lieve Vrouwe Hospital, Aalst, the Netherlands; 17. Department of Cardiology, Sint-Jan Hospital, Brugge, Belgium; 18. Department of Cardiology, Institut National de Chirurgie Cardiaque et de Cardiologie Interventionnelle, Luxembourg City, Luxembourg; 19. Department of Cardiology, Hospital Oost-Limburg, Genk, Belgium; 20. Department of Cardiology, University Hospital Galway, Galway, Ireland; 21. Cardiothoracovascular Department, University of Trieste, Trieste, Italy; 22. Department of Functional Coagulation, Synapse Research Institute, Maastricht, the Netherlands; 23. Department of Anesthesiology, Intensive Care Medicine, Emergency Medicine and Pain Therapy, Hospital Oost-Limburg, Genk, Belgium; 24. Cardiovascular Research Institute Maastricht (CARIM), Maastricht, the Netherlands
About one-third of patients undergoing transcatheter aortic valve implantation (TAVI) use oral anticoagulants (OAC), mainly due to atrial fibrillation. General guidelines advise interrupting OAC in patients with a high risk of bleeding undergoing interventions. However, preliminary observational data suggest that the continuation of OAC during TAVI is safe and may reduce the risk of periprocedural thromboembolic events. The Periprocedural Continuation Versus Interruption of Oral Anticoagulant Drugs During Transcatheter Aortic Valve Implantation (POPular PAUSE TAVI) is a multicentre, randomised clinical trial with open-label treatment and blinded endpoint assessment. Patients are randomised 1:1 to periprocedural continuation versus interruption of OAC and are stratified for vitamin K antagonist or direct oral anticoagulant use. The primary endpoint is a composite of cardiovascular mortality, all stroke, myocardial infarction, major vascular complications and type 2-4 bleeding within 30 days after TAVI, according to the Valve Academic Research Consortium-3 criteria. Secondary endpoints include separate individual and composite outcomes, quality of life and cost-effectiveness. Since continuation of OAC is associated with the ancillary benefit that it simplifies periprocedural management, the primary outcome is first analysed for non-inferiority; if non-inferiority is proven, superiority will be tested. Recruitment started in November 2020, and the trial will continue until a total of 858 patients have been included and followed for 90 days. In summary, POPular PAUSE TAVI is the first randomised clinical trial to assess the safety and efficacy of periprocedural continuation versus interruption of OAC in patients undergoing TAVI.
No account yet?
Sign up for free!
Create my pcr account
Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases
from PCRonline.com
bleedingstroketavi
Read next article
A nationwide analysis of reperfusion therapies for pulmonary embolism in older patients with frailty